MK-677: The Oral Secretagogue That Mimics Your Body’s Natural Growth Signals
LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.
Key Takeaways
- It changes hormone signals, rather than providing growth hormone directly. MK-677, also called ibutamoren, is an oral, non-peptide compound that mimics part of ghrelin’s signal. In clinical studies, this raised growth hormone and insulin-like growth factor 1 (IGF-1) levels.1,2
- The potential benefits and results need context. A 12-month study in healthy older adults found higher fat-free mass, but not better strength or physical function. It also did not find lower total body fat, so the research does not support simple claims about muscle gain or fat loss.1
- Side effects are part of the picture. Research reported increased appetite, mild leg swelling, muscle pain, higher fasting blood sugar, and lower insulin sensitivity. These concerns deserve extra attention for people with diabetes, prediabetes, or cardiovascular risk factors.1,4
- The regulatory status is an essential part of the story. MK-677 is not FDA approved for any use. The FDA says its safety and effectiveness have not been established and has identified potential safety concerns, including a possible risk of congestive heart failure in certain people.4,5
What is MK-677?
MK-677, also known by the name ibutamoren, belongs to a class of compounds known as growth hormone secretagogues (GHS). While it is often grouped with peptides like ipamorelin or CJC-1295, it is structurally distinct. MK-677 is a small, non-peptide molecule designed to survive the digestive system, allowing it to be taken in investigational settings as a pill while still reaching the brain and pituitary gland effectively.
One of its most defining characteristics is its long half-life of approximately 24 hours, which allows for a single daily dose to maintain elevated levels of insulin-like growth factor 1 (IGF-1) throughout the day. Despite its popularity in certain wellness circles, it is important to note that MK-677 remains an investigational compound and is not FDA-approved for any medical use. It is also frequently mislabeled as a SARM (selective androgen receptor modulator), though it does not interact with androgen receptors at all.
Fast Facts
| FULL NAME | MK-677 (ibutamoren; also known as L-163,191) |
| CLASS | Non-peptide ghrelin receptor agonist; oral growth hormone secretagogue |
| PRIMARY ACTION | Binds to GHS-R1a receptors to trigger pulsatile growth hormone release and sustained IGF-1 elevation |
| ADMINISTRATION | Investigational, swallowed in research settings |
| HALF-LIFE | About 24 hours |
| RESEARCH | Age-related muscle loss, bone density, nitrogen balance, and metabolic rate |
| REGULATORY STATUS | Investigational; not FDA approved for any indication |
How Does MK-677 Work?
The mechanism behind MK-677 is centered on its ability to mimic ghrelin, a hormone produced in the stomach that is best known for its role in signaling hunger. However, ghrelin also serves as a critical regulator of the growth hormone axis by traveling to the brain and binding to specific receptors.
MK-677 works by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and the hypothalamus. By mimicking ghrelin at this receptor, it signals the pituitary to release growth hormone in a series of natural-feeling pulses. This is a key distinction from direct growth hormone injections, which provide a flat, constant level of the hormone that can sometimes suppress the body’s own production over time.1
Once the growth hormone is released, it travels to the liver and triggers the production of insulin-like growth factor 1 (IGF-1). Because MK-677 has a long half-life, it provides a sustained signal that keeps IGF-1 levels elevated for a full 24 hours. This sustained elevation is associated with many of the primary effects seen in research, such as changes in muscle mass and bone remodeling.1,2
Unlike some synthetic growth signals, MK-677 does not override the body’s natural “brakes.” The hormone somatostatin, which acts to stop growth hormone release when levels are high enough, remains active. This ensures that the growth hormone is released in a pulsatile manner that respects the body’s internal feedback loops, reducing the risk of the extreme hormonal imbalances seen with some older compounds.1
The structural design of MK-677 allows it to bypass the need for injections entirely. Most growth hormone secretagogues are peptides, which are broken down by stomach acid before they can reach the bloodstream. MK-677 was specifically engineered as a non-peptide molecule that remains stable in the digestive tract, making it the only compound in its class that can be effectively swallowed.1
What Does the Research Say About MK-677?
The research on MK-677 is particularly robust because it has been evaluated in several long-term, randomized controlled trials involving human participants. These studies have primarily focused on how the compound affects body composition, bone health, and metabolic function in different populations.
| THERAPEUTIC AREA | WHAT RESEARCH SUGGESTS | EVIDENCE LEVEL |
|---|---|---|
| Lean Mass | Average gain of 1.1 kg in healthy older adults over a period of 12 months.1 | Clinical Trials |
| Bone Density | Increased markers of bone remodeling and mineral density in the hip.1 | Clinical Trials |
| Metabolic Rate | Significant increase in basal metabolic rate within two weeks in obese subjects.2 | Clinical Trials |
| Muscle Preservation | Reversal of nitrogen wasting during periods of low-calorie dieting.3 | Clinical Trials |
Primary Areas of Study
The most cited research on MK-677 is a 12-month clinical trial involving healthy older adults. In this study, participants taking 25 mg of MK-677 daily gained an average of 1.1 kg of lean mass, while the placebo group actually lost muscle mass over the same period. This suggests that the compound was associated with a reversal of age-related muscle loss. However, it is important to note that total body weight also increased, and the compound was not associated with a significant reduction in total body fat in this population.1
Beyond muscle, research has explored how MK-677 influences bone health. In the same 12-month trial, researchers observed a significant increase in markers of bone remodeling. Over time, this was associated with an increase in bone mineral density, particularly in the femoral neck (the hip area). This has led to interest in the compound as a potential tool for addressing the bone thinning that’s common with aging.1,2
In studies involving obese individuals, short-term use of MK-677 was associated with a significant rise in the basal metabolic rate. This increase in calorie burning at rest was noted within just two weeks of starting the compound. Furthermore, research has shown that MK-677 can help the body hold onto protein more effectively during periods of caloric restriction, which is a critical factor in preserving muscle during weight loss or recovery from illness.2,3
Is MK-677 Safe?
In clinical trials, MK-677 was generally described as having a manageable safety profile, though it is associated with several specific side effects that require careful monitoring. The most common issues reported by participants included a significant increase in appetite, temporary swelling in the legs, and mild muscle aches during the initial weeks of use.1
Important Considerations
The most significant metabolic concern found in research is a modest increase in fasting blood glucose levels and a decrease in insulin sensitivity. In long-term trials, fasting glucose rose by an average of 5 mg/dL. For individuals with prediabetes or a family history of metabolic issues, this is a critical area that requires medical oversight.
MK-677 is strictly an investigational compound. It has not been approved by the FDA for the treatment of any medical condition and cannot be legally marketed as a drug or dietary supplement.
Any use of MK-677 should be considered purely investigational and should only occur under the direct supervision of a licensed physician who can monitor metabolic markers and overall health.
Because it mimics the hunger hormone ghrelin, MK-677 is associated with a significant increase in appetite. This can lead to total weight gain, which may not be desirable, particularly for people focused on fat loss.
Before considering any compound that influences the growth hormone axis, a thorough evaluation by a healthcare provider is necessary to ensure it is appropriate for your specific health profile and to address potential risks.
The Bottom Line
MK-677 holds a genuinely interesting place among growth hormone secretagogues. It is the only compound in this class with a real body of human clinical trial data, and the only one that can be taken by mouth. In randomized controlled trials, MK-677 was associated with increases in lean mass, elevated IGF-1, and preservation of lean tissue during caloric restriction.1,2,3
At the same time, it is not FDA-approved, its effects on blood sugar are a consistent concern, and the long-term safety picture in humans is not yet fully known. The research covers up to 12 months of use, which is meaningful but not enough to draw conclusions about what happens over many years.
For clinicians and patients exploring growth hormone secretagogues, MK-677 is one of the better-studied options available. But that evidence comes with real caveats, and any use outside of a clinical trial or supervised medical setting carries regulatory and safety risks that should not be taken lightly. As with all investigational compounds, the right place to start is with a qualified healthcare provider who can weigh the individual’s situation against the current data.
Scientific References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9):601-611.
- Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, insulin-like growth factor-I, and basal metabolic rate, and modifies body composition. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362-369.
- Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an oral growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):320-325.
- US Food and Drug Administration. Agebox Inc. MARCS-CMS 718252 – December 19, 2025. Updated December 30, 2025.
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Updated April 22, 2026. Accessed September 21, 2026.
©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.
FAQ
MK-677, also called ibutamoren, is a lab-made, non-peptide growth hormone secretagogue. A secretagogue is a compound that signals the body to release a hormone. What does MK-677 do? It acts as an oral ghrelin mimetic, which means it copies part of the signal from ghrelin, a hormone involved in appetite and growth hormone release. In clinical studies, it increased growth hormone and IGF-1 levels.
No. MK-677 is a non-peptide compound, not a peptide or an anabolic steroid. It is also different from a selective androgen receptor modulator (SARM), which is a separate class of investigational compounds that act through androgen receptors. MK-677 is studied as a growth hormone secretagogue, meaning its main research interest is its effect on growth hormone signaling.
The research is more nuanced than many online claims suggest. In one 12-month study of healthy older adults, MK-677 increased fat-free mass by an average of 1.1 kg, but it did not improve strength or physical function. Participants also gained body weight, and researchers did not find a significant reduction in total or abdominal fat. A separate, short study in obese men found higher fat-free mass but no significant change in total or visceral fat. In another small trial, eight healthy volunteers had less protein loss during short-term calorie restriction, but that result does not establish a long-term muscle or performance benefit.
Reported MK-677 side effects include increased appetite, temporary mild leg swelling, fatigue, and muscle pain. In the 12-month study, fasting blood glucose increased and insulin sensitivity declined. The FDA also warns that ibutamoren may affect glucose metabolism and has identified a potential congestive heart failure risk in certain people. Because these issues can matter more for people with metabolic or heart-related conditions, this is not a compound to treat casually.
No. MK-677 is not FDA approved for any medical use in the United States, and the FDA says its safety and effectiveness have not been established. There is no FDA-approved dosage, timing schedule, or “cycle.” Doses used in clinical trials were research protocols, not personal dosing guidance. Online products marketed as “supplements” should not be mistaken for FDA-approved or proven therapies.
Related Posts
Beginning a peptide protocol is a highly personalized patient journey, but even the best science needs a
Orexin is drawing new attention in sleep and energy conversations. What the science shows about its affect on wakefulness,
Matrixyl represents a shift in skincare from surface treatments to biological signaling. As a matrikine peptide, it mimics the
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.